Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy.

Liyun ShenLei YeWei ZhuQin JiaoYulin ZhouShu WangWeiqing WangGuang Ning

Published in: European thyroid journal (2022)

Our study shows that reduced MP plus MTX therapy is effective and safer in treating active and moderate-to-severe GO patients than 4.5 g MP monotherapy.

Keyphrases

patient reported
early onset
high intensity
combination therapy
end stage renal disease
high dose
chronic kidney disease
newly diagnosed
ejection fraction
stem cells
prognostic factors
study protocol